Drug interactions - Basic information and aspects specific to intensive care medicine;Arzneimittelinteraktionen: Grundsätze und intensivmedizinische aspekte

Anasthesiologie und Intensivmedizin

Volumn 52, Issue 9, 2011, Pages 694-707

  Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cytochrome P450; Efflux transporter; Induction; Inhibition; Pharmacokinetics

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P;

DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; HOSPITALIZATION; INTENSIVE CARE; QT PROLONGATION; REVIEW;

EID: 80052883987     PISSN: 01705334     EISSN: 14390256     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients: a Meta-Analysis of Prospective Studies. JAMA 1998;279:1200-1205. (Pubitemid 28193431)
2. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. Ann Pharmacother 2007; 41:1411-1426. (Pubitemid 47311361)
3. Smith FA, Wittmann CW, Stern TA. Medical Complications of Psychiatric Treatment. Crit Care Clin 2008;24:635-656.
4. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse Drug Reactions in Hospital In-Patients: a Prospective Analysis of 3695 Patient-Episodes. PLoS One 2009;4:e4439.
5. Moore TJ, Cohen MR, Furberg CD. Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-1759.
6. Gallagher PF, Barry PJ, Ryan C, Hartigan I, O'Mahony D. Inappropriate Prescribing in an Acutely Ill Population of Elderly Patients as Determined by Beers' Criteria. Age Ageing 2008;37:96-101. (Pubitemid 351146983)
7. Gonzalez C, Penado S, Llata L, Valero C, Riancho JA. The Clinical Spectrum of Retroperitoneal Hematoma in Anticoagulated Patients. Medicine (Baltimore) 2003;82:257-262. (Pubitemid 36859221)
8. Li L, Yu M, Chin R, Lucksiri A, Flockhart DA, Hall SD. Drug-Drug Interaction Prediction: a Bayesian Meta-Analysis Approach. Stat Med 2007;26:3700-3721.
9. Bertz RJ, Granneman GR. Use of in Vitro and in Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin Pharmacokinet 1997;32:210-258. (Pubitemid 27122521)
10. Ingelman-Sundberg M. Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions. N Engl J Med 2008; 358:637-639. (Pubitemid 351214293)
11. Ma Q. Xenobiotic-Activated Receptors: From Transcription to Drug Metabolism to Disease. Chem Res Toxicol 2008;21:1651-1671.
12. Ho RH, Kim RB. Transporters and Drug Therapy: Implications for Drug Disposition and Disease. Clin Pharmacol Ther 2005;78:260-277.
13. Cascorbi I. Role of Pharmacogenetics of ATP-Binding Cassette Transporters in the Pharmacokinetics of Drugs. Pharmacol Ther 2006;112:457-473. (Pubitemid 44486412)
14. Lotsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G, et al. Increased CNS Uptake and Enhanced Antinociception of Morphine-6- Glucuronide in Rats After Inhibition of P-Glycoprotein. J Neurochem 2002;83:241-248. (Pubitemid 35191390)
15. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The Role of Intestinal P-Glycoprotein in the Interaction of Digoxin and Rifampin. J Clin Invest 1999;104:147-153.
16. Geick A, Eichelbaum M, Burk O. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin. J Biol Chem 2001;276:14581-14587.
17. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, et al. Carbamazepine Regulates Intestinal P-Glycoprotein and Multidrug Resistance Protein MRP2 and Influences Disposition of Talinolol in Humans. Clin Pharmacol Ther 2004;76:192-200. (Pubitemid 39221793)
18. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute Heart Transplant Rejection Due to Saint John's Wort. Lancet 2000;355: 548-549. (Pubitemid 30088678)
19. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters. Am J Pathol 2000;157:1575-1580.
20. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs As CYP3A Probes, Inducers, and Inhibitors. Drug Metab Rev 2007;39: 699-721.
21. Shakeri-Nejad K, Stahlmann R. Drug Interactions During Therapy With Three Major Groups of Antimicrobial Agents. Expert Opin Pharmacother 2006;7:639-651.
22. Geronimo-Pardo M, Cuartero-del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R. Clarithromycin-Nifedipine Interaction As Possible Cause of Vasodilatory Shock. Ann Pharmacother 2005;39:538-542. (Pubitemid 40270922)
23. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with Fluoroquinolones, Sulfonamides, or Azole Antifungals: Interactions and the Risk of Hospita lization for Gastrointestinal Bleeding. Clin Pharmacol Ther 2008;84:581-588.
24. Molden E, Skovlund E, Braathen P. Risk Management of Simvastatin or Atorvastatin Interactions With CYP3A Inhibitors. Drug Saf 2008;31:587-596. (Pubitemid 351861951)
25. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, et al. Lack of Pantoprazole Drug Interactions in Man. Int J Clin Pharmacol Ther 1994; 32:385-399. (Pubitemid 24241638)
26. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. Increase of Cytochrome P450IA2 Activity by Omeprazole: Evidence by the 13C-(-3-Methyl)-Caffeine Breath Test in Poor and Extensive Metabolizers of S-Mephenytoin. Clin Pharmacol Ther 1992; 52:170-180.
27. Dilger K, Zheng Z, Klotz U. Lack of Drug Interaction Between Omeprazole, Lansoprazole, Pantoprazole and Theophylline. Br J Clin Pharmacol 1999; 48:438-444. (Pubitemid 29417730)
28. Rost KL, Fuhr U, Thomsen T, Zaigler M, Brockmoller J, Bohnemeier H, et al. Omeprazole Weakly Inhibits CYP1A2 Activity in Man. Int J Clin Pharmacol Ther 1999;37:567-574. (Pubitemid 29524975)
29. Meyer UA. Metabolic Interactions of the Proton-Pump Inhibitors Lansoprazole, Omeprazole and Pantoprazole with Other Drugs. Eur J Gastroenterol Hepatol 1996;8 Suppl 1:S21-S25.
30. Lane RM. Pharmacokinetic Drug Interaction Potential of Selective Serot onin Reuptake Inhibitors. Int Clin Psychopharmacol 1996;11 Suppl 5:31-61. (Pubitemid 27049280)
31. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A Fatal Drug Interaction Between Clozapine and Fluoxetine. J Forensic Sci 1998;43:1082-1085.
32. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study. BMJ 2010;340:c693.
33. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, et al. Time Course of Recovery of Cytochrome P450 3A Function After Single Doses of Grapefruit Juice. Clin Pharmacol Ther 2003;74:121-129. (Pubitemid 36951809)
34. Courade JP, Chassaing C, Bardin L, Alloui A, Eschalier A. 5-HT Receptor Subtypes Involved in the Spinal Antinociceptive Effect of Acetaminophen in Rats. Eur J Pharmacol 2001;432:1-7. (Pubitemid 33153126)
35. Pickering G, Esteve V, Loriot MA, Eschalier A, Dubray C. Acetaminophen Reinforces Descending Inhibitory Pain Pathways. Clin Pharmacol Ther 2008;84:47-51.
36. Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic Effect of Acetaminophen in Humans: First Evidence of a Central Serotonergic Mechanism. Clin Pharmacol Ther 2006;79:371-378.
37. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient- Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes. J Clin Oncol 2002;20:2805-2811. (Pubitemid 34651509)
38. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N Engl J Med 2001;345:1809-1817.